Table 1 Patient demographics and clinical characteristics

From: A phase I study of an adenoviral vector delivering a MUC1/CD40-ligand fusion protein in patients with advanced adenocarcinoma

 

Number of patients (%) N = 21

Total number of patients

21 (100)

Age at consent

Median (IQR)

60 (51.0, 65.0)

Range

34–88

Gender

Male

1 (4.8)

Female

20 (95.2)

Ethnic group

Chinese

16 (76.2)

Indian

1 (4.8)

Others

4 (19.0)

Primary disease site

Breast

13 (61.9)

Lung

1 (4.8)

Ovary

7 (33.3)

ECOG performance status

0

6 (28.6)

1

15 (71.4)

Number of prior lines of treatment

Median

3

Range

0 – 10

Baseline CA 15-3, U/ml (Lab reference value < 25.1 U/ml)

Median (IQR)

37.2 (21.7–101.0)

Range

11.6–634.0